Li M, Sack JS, Rahma OE, Hodi FS, et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020 Sep 5. doi: 10.1002/cncr.33165.
PMID: 32888341